These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 11418315

  • 1. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR.
    Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
    Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ.
    Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
    [Abstract] [Full Text] [Related]

  • 3. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 4. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-López AJ, Witzig TE, White CA.
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [Abstract] [Full Text] [Related]

  • 5. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
    Wiseman GA, Leigh BR, Dunn WL, Stabin MG, White CA.
    Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
    [Abstract] [Full Text] [Related]

  • 6. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
    Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, Silverman DH, Witzig TE, Sparks RB, White CA.
    Cancer; 2002 Feb 15; 94(4 Suppl):1349-57. PubMed ID: 11877765
    [Abstract] [Full Text] [Related]

  • 7. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
    Krasner C, Joyce RM.
    Curr Pharm Biotechnol; 2001 Dec 15; 2(4):341-9. PubMed ID: 11762415
    [Abstract] [Full Text] [Related]

  • 8. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA.
    J Clin Oncol; 2002 May 15; 20(10):2453-63. PubMed ID: 12011122
    [Abstract] [Full Text] [Related]

  • 9. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
    Alcindor T, Witzig TE.
    Curr Treat Options Oncol; 2002 Aug 15; 3(4):275-82. PubMed ID: 12074764
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, vande Ven C, Perkins SL, Cairo MS, Children's Oncology Group.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
    Witzig TE.
    Cancer Chemother Pharmacol; 2001 Aug 15; 48 Suppl 1():S91-5. PubMed ID: 11587375
    [Abstract] [Full Text] [Related]

  • 12. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
    Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C.
    Clin Lymphoma; 2004 Sep 15; 5(2):98-101. PubMed ID: 15453924
    [Abstract] [Full Text] [Related]

  • 13. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA.
    J Clin Oncol; 2002 Aug 01; 20(15):3262-9. PubMed ID: 12149300
    [Abstract] [Full Text] [Related]

  • 14. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
    Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ.
    Cancers (Basel); 2021 Jun 06; 13(11):. PubMed ID: 34204102
    [Abstract] [Full Text] [Related]

  • 15. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
    Witzig TE.
    Drugs Today (Barc); 2004 Feb 06; 40(2):111-9. PubMed ID: 15045033
    [Abstract] [Full Text] [Related]

  • 16. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
    Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, Papi S, Prisco G, Ferrucci PF, Martinelli G, Paganelli G.
    J Nucl Med; 2007 Nov 06; 48(11):1871-9. PubMed ID: 17978355
    [Abstract] [Full Text] [Related]

  • 17. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE.
    Semin Oncol; 2000 Dec 06; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [Abstract] [Full Text] [Related]

  • 18. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
    Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA.
    Blood; 2002 Jun 15; 99(12):4336-42. PubMed ID: 12036859
    [Abstract] [Full Text] [Related]

  • 19. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
    Hagenbeek A.
    Leuk Lymphoma; 2003 Jun 15; 44 Suppl 4():S37-47. PubMed ID: 15154741
    [Abstract] [Full Text] [Related]

  • 20. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
    Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS.
    J Clin Oncol; 2003 Apr 01; 21(7):1263-70. PubMed ID: 12663713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.